John Kolawole, MD
Interventional Cardiology · Montgomery, ALNPI 1285086504
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Shockwave Medical, Inc at 38.7% of the total. Reporting peaked in 2024 at $13,110 and has fallen 64.2% since, to $4,695 in 2025.
Across 225 payments — averaging $100.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$9K
- Medtronic$3K
- Penumbra, Inc.$3K
- Abiomed$1K
- Boston Scientific$1K
- Edwards Lifesciences$1K
- plus $4K from 23 others
What the payments were for
- Speaking & faculty fees$6,60029%
- Travel & lodging$7,96635%
- Food & beverage$8,11736%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 14 | $8,775 |
| Medtronic | 35 | $3,360 |
| Penumbra, Inc. | 6 | $2,776 |
| Abiomed | 12 | $1,267 |
| Boston Scientific | 6 | $1,238 |
| Edwards Lifesciences | 11 | $1,040 |
| AstraZeneca | 18 | $961 |
| Inari Medical, Inc. | 5 | $489 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $462 |
| Boehringer Ingelheim | 16 | $432 |
| Pfizer | 13 | $300 |
| Lantheus Medical Imaging, Inc. | 4 | $238 |
| Novartis | 13 | $222 |
| Amgen | 13 | $194 |
| E.r. Squibb & Sons, L.L.C. | 10 | $143 |
| Philips North America LLC | 6 | $121 |
| Livanova USA, Inc. | 1 | $107 |
| Irhythm Technologies, Inc. | 2 | $102 |
| Bayer | 1 | $88 |
| Johnson & Johnson | 3 | $71 |
| Impulse Dynamics (USA) Inc. | 3 | $63 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Merck | 2 | $35 |
| Akcea Therapeutics, Inc. | 2 | $31 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Vivus LLC | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Cardiovascular Systems Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$8,432
- Indigo System$2,776
- TurboHawk$2,344
- Impella$995
- VersaCross Access Solution$980
- FLOWTRIEVER CATHETER, S$573
- FARXIGA$465
- CT THROMBECTOMY SYSTEM KIT$330
- BRILINTA$247
- Definity$120
- TandemLife$107
- ELUVIA$101
How this compares
$22,682 in reported general payments places this provider in the 80th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 102 | $72,640 |
| EntrestoSacubitril/Valsartan | 35 | $35,147 |
| FarxigaDapagliflozin Propanediol | 20 | $17,030 |
| Ranolazine ErRanolazine | 12 | $2,009 |
| Atorvastatin Calcium | 122 | $1,717 |
| Metoprolol Succinate | 105 | $1,585 |
| Amiodarone Hcl | 27 | $1,328 |
| Carvedilol | 104 | $963 |
| Rosuvastatin Calcium | 20 | $780 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 18 | $697 |
| ClopidogrelClopidogrel Bisulfate | 64 | $691 |
| Losartan Potassium | 63 | $672 |
| Amlodipine Besylate | 46 | $580 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 24 | $557 |
| Hydralazine Hcl | 20 | $410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $300 | $72,640102 claims |
| NovartisEntresto | $222 | $35,14735 claims |
| AstraZenecaFarxiga | $961 | $17,03020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Montgomery
- Sergio Perez BeracasaMontgomery$25K
- Taimoor HashimMontgomery$12K
- Thomas WoolMontgomery$8K
- Ashwini SharmaMontgomery$8K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- John GallaMobile$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.